From: Long-term (5 year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial
Year 1 a | Year 2 | Year 3 | Year 4 b | Year 5 b | ||||
---|---|---|---|---|---|---|---|---|
Adverse Event | BT (n = 45) | Control (n = 24) | BT (n = 45) | Control (n = 24) | BT (n = 43) | Control (n = 21) | BT (n = 43) | BT (n = 42) |
Dyspnea | 19 (42.2%) | 12 (50.0%) | 4 (8.9%) | 3 (12.5%) | 4 (9.3%) | 3 (14.3%) | 4 (9.3%) | 4 (9.5%) |
Cough | 17 (37.8%) | 7 (29.2%) | 4 (8.9%) | 1 (4.2%) | 2 (4.7%) | 3 (14.3%) | 3 (7.0%) | 2 (4.8%) |
Wheeze | 14 (31.1%) | 4 (16.7%) | 2 (4.4%) | 1 (4.2%) | 3 (7.0%) | 1 (4.8%) | 3 (7.0%) | 2 (4.8%) |
Nasal congestion | 13 (28.9%) | 5 (20.8%) | 2 (4.4%) | 0 | 0 | 0 | 0 | 1 (2.4%) |
Upper Respiratory Tract Infection | 10 (22.2%) | 2 (8.3%) | 11 (24.4%) | 4 (16.7%) | 8 (18.6%) | 4 (19.1%) | 8 (18.6%) | 4 (9.5%) |
Productive cough | 9 (20.0%) | 5 (20.8%) | 2 (4.4%) | 1 (4.2%) | 2 (4.7%) | 0 | 0 | 1 (2.4%) |
Chest discomfort | 8 (17.8%) | 3 (12.5%) | 2 (4.4%) | 2 (8.3%) | 3 (7.0%) | 1 (4.8%) | 1 (2.3%) | 2 (4.8%) |
Nasopharyngitis | 6 (13.3%) | 0 | 1 (2.2%) | 0 | 0 | 0 | 1 (2.3%) | 1 (2.4%) |
Nocturnal Dyspnea | 6 (13.3%) | 2 (8.3%) | 0 | 0 | 0 | 0 | 0 | 0 |
Respiratory Tract Infection c | 5 (11.1%) | 5 (20.8%) | 3 (6.7%) | 2 (8.3%) | 5 (11.6%) | 1 (4.8%) | 5 (11.6%) | 4 (9.5%) |
Pharyngolaryngeal pain | 5 (11.1%) | 3 (12.5%) | 0 | 0 | 0 | 0 | 0 | 0 |
Respiratory Tract congestion | 4 (8.9%) | 2 (8.3%) | 0 | 0 | 0 | 0 | 0 | 0 |
Discolored sputum | 4 (8.9%) | 0 | 3 (6.7%) | 0 | 0 | 0 | 0 | 0 |
Rhinitis | 2 (4.4%) | 0 | 0 | 0 | 1 (2.3%) | 0 | 0 | 2 (4.8%) |
Bronchitis d | 1 (2.2%) | 0 | 1 (2.2%) | 1 (4.2%) | 1 (2.3%) | 2 (9.5%) | 1 (2.3%) | 1 (2.4%) |
Pharyngitis | 1 (2.2%) | 1 (4.2%) | 0 | 0 | 0 | 0 | 0 | 0 |
Pleuritic Pain | 1 (2.2%) | 1 (4.2%) | 0 | 0 | 0 | 0 | 0 | 0 |
Rhinorrhea | 1 (2.2%) | 1 (4.2%) | 0 | 0 | 1 (2.3%) | 0 | 0 | 0 |
Asthma (multiple symptoms) e | 0 | 0 | 4 (8.9%) | 2 (8.3%) | 7 (16.3%) | 1 (4.8%) | 7 (16.3%) | 6 (14.3%) |
Sinusitis | 0 | 0 | 1 (2.2%) | 1 (4.2%) | 2 (4.7%) | 0 | 2 (4.7%) | 2 (4.8%) |
Nasal polyps | 0 | 0 | 1 (2.2%) | 0 | 0 | 0 | 2 (4.7%) | 0 |
Pneumonia | 0 | 0 | 0 | 0 | 1 (2.3%) | 1 (4.8%) | 0 | 0 |